Menu
Non-Surgical Solution
XP37 offers a non-invasive alternative to surgery, reducing the risk of complications and the need for postoperative care.
Addressing Root Causes
Unlike traditional treatments that may only address symptoms, XP37 tackles the underlying mechanisms of pterygium by stopping abnormal blood vessel growth.
Recurrence Risk
Traditional treatments, such as surgery, often face the challenge of pterygium recurrence, whereas XP37 can enhance overall patient well-being and quality of life by minimizing the need for repeated interventions.
Pterygium is an ocular surface disease characterized mainly by a wing-shaped growth of tissue. This raised, fleshy growth is rich in blood vessels and begins in the conjunctiva, the transparent membrane covering the white part of the eye and gradually spreading over the adjacent cornea. A pterygium can range from a transparent area with a few blood vessels to a thick opaque growth that can obstruct vision. They can occur in one or both eyes. Initially, it might not cause any symptoms or discomfort. However, when inflamed, one may experience symptoms such as redness, irritation, foreign body sensation, and blurred vision. Extended exposure to ultraviolet (UV) light and environmental factors such as dust, wind, and dry climates are believed to contribute to its development.
Pterygium may be associated with having a shorter axial length in the eyes (small eyes).
Pterygium is a common ocular condition with a global prevalence of up to 33%, potentially affecting around 200 million people worldwide.
XP37 eye drops provide an innovative solution for managing pterygium. This treatment targets the anterior segment of the eye, blocking angiogenesis—the formation of new blood vessels—crucial in pterygium progression. By inhibiting this process, XP37 reduces the growth of abnormal blood vessels that extend over the cornea. This action alleviates inflammation and halts the progression of the growth, addressing the root cause rather than just the symptoms.
XP37 eye drops present a non-surgical, effective treatment option for pterygium, targeting its underlying mechanisms. This promising therapy offers hope for better management, improving patients’ quality of life and minimizing the need for invasive procedures.